Why AI-led drug discovery is a hiring inflection point for Life Sciences start-ups
By Jack Wilson. Across the life sciences sector, there’s a clear shift underway in how organisations think about data, AI, and machine learning. What was once experimental or exploratory is now becoming foundational infrastructure for a growing class of platform-led...
The opportunity and the bottleneck. Where talent really matters in AI driven drug discovery
By James Trott, Founder, Aspire Life Sciences Search Over the past twelve to eighteen months, the narrative in biotech and pharma has shifted quickly. A series of high-profile partnerships and data platform initiatives between major pharmaceutical companies and...
What we learned from JPM 2026
The 2026 JPM Healthcare Conference reinforced that the healthcare and life sciences sector has entered a more disciplined, execution-led phase. While previous years were defined by headline-grabbing M&A and exuberant valuations, JPM 2026 was about proof points:...